Can you name the first cancer keytruda was approved to treat?

The first cancer Keytruda was approved to treat was melanoma. The FDA gave approval in September 2014 for patients with advanced melanoma who had progressed after treatment with ipilimumab and, if BRAF V600E/K mutation-positive, also after treatment with a BRAF inhibitor.

Why did the FDA approve Keytruda so early?

Keytruda was cleared on the basis of a single-arm phase 1 trial known as KEYNOTE-001. The trial showed an objective response rate of 24 percent in previously treated patients, with some responses lasting over a year. The agency accepted this small dataset because melanoma lacked effective options at the time and Keytruda showed durable responses in a subset of patients.

What happened to Keytruda after its melanoma approval?

After the 2014 melanoma approval, Keytruda received subsequent approvals for non-small cell lung cancer in 2015, head and neck squamous cell cancer in 2016, classical Hodgkin lymphoma in 2017, and many other indications. By 2024, Keytruda had more than 30 FDA-approved indications spanning almost every major tumor type.

What happened if a patient had melanoma before Keytruda existed?

Patients with advanced melanoma before 2014 faced a mean survival time of less than six months. The introduction of checkpoint inhibitors like Keytruda and Yervoy changed the five-year survival rate for metastatic melanoma from below 10 percent to above 30 percent in some cohorts.

When does Keytruda's patent expire?

Keytruda's composition-of-matter patent expires in 2028, but Merck holds a family of patents covering formulations, methods of treatment, and use of PD-1/PDL1 pairing diagnostics. These secondary patents may push exclusivity into the 2030s. Early reports suggest biosimilar challengers will begin filing in 2026.

Why are companies challenging this patent?

Merck is defending the exclusivity of Keytruda in court and at the Patent Trial and Appeal Board. The challenges include attacks on the secondary patents that cover the use of PD-1/PDL1 diagnostics and treatment methods. Some challengers are laying groundwork for biosimilar launches after 2028.

How does this drug compare with Keytruda?

Keytruda is the original pembrolizumab product marketed by Merck. No direct comparison across the same patient cohort is available, but Keytruda itself is the benchmark for all subsequent PD-1 inhibitors including Opdivo, Libtayo, and Jynedo.

How does Keytruda compare with Opdivo?

Opdivo (nivolumab) was approved shortly after Keytruda for melanoma and lung cancer. They both block the PD-1 pathway and show similar efficacy in most indications. The difference between Keytruda and Opdivo is mainly in dosing schedules and licensed indications.